Skip to main content
Top
Published in:

03-01-2024 | Naltrexone

Pharmacological Treatments for Alcohol Use Disorder: Considering the Role of Sex and Gender

Authors: Dylan E. Kirsch, Malia A. Belnap, Elizabeth M. Burnette, Erica N. Grodin, Lara A. Ray

Published in: Current Addiction Reports | Issue 1/2024

Login to get access

Abstract

Purpose of Review

This qualitative literature review examined sex and gender differences in alcohol use disorder (AUD) pharmacotherapy treatment response. Specifically, we reviewed the clinical and preclinical literature evaluating sex and gender differences in responses to US Food and Drug Administration (FDA) and European Medicine Agency (EMA) approved medications, and repurposed, or off-label, medications for the treatment of AUD.

Recent Findings

Despite important sex and gender differences in AUD, the effect of sex and gender in the pharmacological treatment of AUD has been understudied. Relatively low representation of women in clinical studies has limited well powered investigations of gender effects on treatment response. Additionally, most preclinical support for AUD medications comes from studies in males. More recent AUD pharmacotherapy research has identified potential sex and gender differences in the efficacy of several pharmacological treatments for AUD. Although findings are mixed, clinical data suggest naltrexone may be more effective at reducing alcohol use in men, while baclofen may be more effective at reducing alcohol use in women. Preclinical studies have indicated sex-differences in the efficacy of topiramate and mifepristone, with putative higher efficacy of topiramate in males and mifepristone in females.

Summary

Historically, sex and gender differences have not been adequately considered in AUD medication development research. In order to improve translation of preclinical findings and clinical utility, sex and gender must be considered at each stage of drug development research.
Literature
1.
2.
go back to reference Alcohol GBD, Drug UC. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012.CrossRef Alcohol GBD, Drug UC. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012.CrossRef
3.
go back to reference Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiat. 2015;72(8):757–66.CrossRef Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiat. 2015;72(8):757–66.CrossRef
4.
go back to reference Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830–42.PubMedCrossRef Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830–42.PubMedCrossRef
5.
go back to reference Han B, Jones CM, Einstein EB, Powell PA, Compton WM. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiat. 2021;78(8):922–4.CrossRef Han B, Jones CM, Einstein EB, Powell PA, Compton WM. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiat. 2021;78(8):922–4.CrossRef
6.•
go back to reference Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K, et al. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs. 2022;82(3):251–74. Qualitative review discussing the current state of pharmacological treatments for alcohol use disorder.PubMedPubMedCentralCrossRef Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K, et al. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs. 2022;82(3):251–74. Qualitative review discussing the current state of pharmacological treatments for alcohol use disorder.PubMedPubMedCentralCrossRef
7.
go back to reference Witkiewitz K, Roos CR, Mann K, Kranzler HR. Advancing precision medicine for alcohol use disorder: replication and extension of reward drinking as a predictor of naltrexone response. Alcohol Clin Exp Res. 2019;43(11):2395–405.PubMedPubMedCentralCrossRef Witkiewitz K, Roos CR, Mann K, Kranzler HR. Advancing precision medicine for alcohol use disorder: replication and extension of reward drinking as a predictor of naltrexone response. Alcohol Clin Exp Res. 2019;43(11):2395–405.PubMedPubMedCentralCrossRef
8.
go back to reference Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol. 2012;17(3):513–27.PubMedPubMedCentralCrossRef Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol. 2012;17(3):513–27.PubMedPubMedCentralCrossRef
10.
go back to reference Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55(2):81–95.PubMedCrossRef Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55(2):81–95.PubMedCrossRef
11.
go back to reference Slade T, Chapman C, Swift W, Keyes K, Tonks Z, Teesson M. Birth cohort trends in the global epidemiology of alcohol use and alcohol-related harms in men and women: systematic review and metaregression. BMJ Open. 2016;6(10):e011827.PubMedPubMedCentralCrossRef Slade T, Chapman C, Swift W, Keyes K, Tonks Z, Teesson M. Birth cohort trends in the global epidemiology of alcohol use and alcohol-related harms in men and women: systematic review and metaregression. BMJ Open. 2016;6(10):e011827.PubMedPubMedCentralCrossRef
12.
go back to reference Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiat. 2017;74(9):911–23.CrossRef Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiat. 2017;74(9):911–23.CrossRef
13.
go back to reference Sharrett-Field L, Butler TR, Reynolds AR, Berry JN, Prendergast MA. Sex differences in neuroadaptation to alcohol and withdrawal neurotoxicity. Pflügers Arch Eur J Physiol. 2013;465(5):643–54.CrossRef Sharrett-Field L, Butler TR, Reynolds AR, Berry JN, Prendergast MA. Sex differences in neuroadaptation to alcohol and withdrawal neurotoxicity. Pflügers Arch Eur J Physiol. 2013;465(5):643–54.CrossRef
14.•
go back to reference Becker JB, Koob GF. Sex differences in animal models: focus on addiction. Pharmacol Rev. 2016;68(2):242–63. Review discussing basic laboratory evidence for sex and gender differences in addiction.PubMedPubMedCentralCrossRef Becker JB, Koob GF. Sex differences in animal models: focus on addiction. Pharmacol Rev. 2016;68(2):242–63. Review discussing basic laboratory evidence for sex and gender differences in addiction.PubMedPubMedCentralCrossRef
16.
go back to reference Flores-Bonilla A, Richardson HN. Sex differences in the neurobiology of alcohol use disorder. Alcohol Res. 2020;40(2):04.PubMedPubMedCentral Flores-Bonilla A, Richardson HN. Sex differences in the neurobiology of alcohol use disorder. Alcohol Res. 2020;40(2):04.PubMedPubMedCentral
18.
go back to reference Agabio R, Campesi I, Pisanu C, Gessa GL, Franconi F. Sex differences in substance use disorders: focus on side effects. Addict Biol. 2016;21(5):1030–42.PubMedCrossRef Agabio R, Campesi I, Pisanu C, Gessa GL, Franconi F. Sex differences in substance use disorders: focus on side effects. Addict Biol. 2016;21(5):1030–42.PubMedCrossRef
21.
go back to reference Erol A, Karpyak VM. Sex and gender-related differences in alcohol use and its consequences: contemporary knowledge and future research considerations. Drug Alcohol Depend. 2015;156:1–13.PubMedCrossRef Erol A, Karpyak VM. Sex and gender-related differences in alcohol use and its consequences: contemporary knowledge and future research considerations. Drug Alcohol Depend. 2015;156:1–13.PubMedCrossRef
22.
go back to reference Goldstein RB, Dawson DA, Chou SP, Grant BF. Sex differences in prevalence and comorbidity of alcohol and drug use disorders: results from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Stud Alcohol Drugs. 2012;73(6):938–50.PubMedPubMedCentralCrossRef Goldstein RB, Dawson DA, Chou SP, Grant BF. Sex differences in prevalence and comorbidity of alcohol and drug use disorders: results from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Stud Alcohol Drugs. 2012;73(6):938–50.PubMedPubMedCentralCrossRef
23.
go back to reference Guinle MIB, Sinha R. The role of stress, trauma, and negative affect in alcohol misuse and alcohol use disorder in women. Alcohol Res. 2020;40(2):05.PubMedPubMedCentral Guinle MIB, Sinha R. The role of stress, trauma, and negative affect in alcohol misuse and alcohol use disorder in women. Alcohol Res. 2020;40(2):05.PubMedPubMedCentral
24.
go back to reference Boykoff N, Schneekloth TD, Hall-Flavin D, Loukianova L, Karpyak VM, Stevens SR, et al. Gender differences in the relationship between depressive symptoms and cravings in alcoholism. Am J Addict. 2010;19(4):352–6.PubMedPubMedCentralCrossRef Boykoff N, Schneekloth TD, Hall-Flavin D, Loukianova L, Karpyak VM, Stevens SR, et al. Gender differences in the relationship between depressive symptoms and cravings in alcoholism. Am J Addict. 2010;19(4):352–6.PubMedPubMedCentralCrossRef
25.
go back to reference Westermeyer J, Boedicker AE. Course, severity, and treatment of substance abuse among women versus men. Am J Drug Alcohol Abuse. 2000;26(4):523–35.PubMedCrossRef Westermeyer J, Boedicker AE. Course, severity, and treatment of substance abuse among women versus men. Am J Drug Alcohol Abuse. 2000;26(4):523–35.PubMedCrossRef
26.
go back to reference Ceylan-Isik AF, McBride SM, Ren J. Sex difference in alcoholism: who is at a greater risk for development of alcoholic complication? Life Sci. 2010;87(5–6):133–8.PubMedPubMedCentralCrossRef Ceylan-Isik AF, McBride SM, Ren J. Sex difference in alcoholism: who is at a greater risk for development of alcoholic complication? Life Sci. 2010;87(5–6):133–8.PubMedPubMedCentralCrossRef
27.
go back to reference Ruiz SM, Oscar-Berman M, Sawyer KS, Valmas MM, Urban T, Harris GJ. Drinking history associations with regional white matter volumes in alcoholic men and women. Alcohol Clin Exp Res. 2013;37(1):110–22.PubMedCrossRef Ruiz SM, Oscar-Berman M, Sawyer KS, Valmas MM, Urban T, Harris GJ. Drinking history associations with regional white matter volumes in alcoholic men and women. Alcohol Clin Exp Res. 2013;37(1):110–22.PubMedCrossRef
28.
go back to reference Pfefferbaum A, Rosenbloom M, Deshmukh A, Sullivan EV. Sex differences in the effects of alcohol on brain structure. Am J Psychiatry. 2001;158(2):188–97.PubMedCrossRef Pfefferbaum A, Rosenbloom M, Deshmukh A, Sullivan EV. Sex differences in the effects of alcohol on brain structure. Am J Psychiatry. 2001;158(2):188–97.PubMedCrossRef
29.
go back to reference Demirakca T, Ende G, Kämmerer N, Welzel-Marquez H, Hermann D, Heinz A, et al. Effects of alcoholism and continued abstinence on brain volumes in both genders. Alcohol Clin Exp Res. 2011;35(9):1678–85.PubMed Demirakca T, Ende G, Kämmerer N, Welzel-Marquez H, Hermann D, Heinz A, et al. Effects of alcoholism and continued abstinence on brain volumes in both genders. Alcohol Clin Exp Res. 2011;35(9):1678–85.PubMed
30.
go back to reference Mann K, Ackermann K, Croissant B, Mundle G, Nakovics H, Diehl A. Neuroimaging of gender differences in alcohol dependence: are women more vulnerable? Alcohol Clin Exp Res. 2005;29(5):896–901.PubMedCrossRef Mann K, Ackermann K, Croissant B, Mundle G, Nakovics H, Diehl A. Neuroimaging of gender differences in alcohol dependence: are women more vulnerable? Alcohol Clin Exp Res. 2005;29(5):896–901.PubMedCrossRef
31.
go back to reference Hommer DW, Momenan R, Kaiser E, Rawlings RR. Evidence for a gender-related effect of alcoholism on brain volumes. Am J Psychiatry. 2001;158(2):198–204.PubMedCrossRef Hommer DW, Momenan R, Kaiser E, Rawlings RR. Evidence for a gender-related effect of alcoholism on brain volumes. Am J Psychiatry. 2001;158(2):198–204.PubMedCrossRef
32.
go back to reference Medina KL, McQueeny T, Nagel BJ, Hanson KL, Schweinsburg AD, Tapert SF. Prefrontal cortex volumes in adolescents with alcohol use disorders: unique gender effects. Alcohol Clin Exp Res. 2008;32(3):386–94.PubMedPubMedCentralCrossRef Medina KL, McQueeny T, Nagel BJ, Hanson KL, Schweinsburg AD, Tapert SF. Prefrontal cortex volumes in adolescents with alcohol use disorders: unique gender effects. Alcohol Clin Exp Res. 2008;32(3):386–94.PubMedPubMedCentralCrossRef
34.
go back to reference Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW, et al. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res. 2001;25(4):502–7.PubMedCrossRef Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW, et al. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res. 2001;25(4):502–7.PubMedCrossRef
35.
go back to reference Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990;322(2):95–9.PubMedCrossRef Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990;322(2):95–9.PubMedCrossRef
36.
go back to reference Becker JB, Perry AN, Westenbroek C. Sex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesis. Biol Sex Differ. 2012;3(1):14.PubMedPubMedCentralCrossRef Becker JB, Perry AN, Westenbroek C. Sex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesis. Biol Sex Differ. 2012;3(1):14.PubMedPubMedCentralCrossRef
38.
go back to reference Schick MR, Spillane NS, Hostetler KL. A call to action: a systematic review examining the failure to include females and members of minoritized racial/ethnic groups in clinical trials of pharmacological treatments for alcohol use disorder. Alcohol Clin Exp Res. 2020;44(10):1933–51. https://doi.org/10.1111/acer.14440. Schick MR, Spillane NS, Hostetler KL. A call to action: a systematic review examining the failure to include females and members of minoritized racial/ethnic groups in clinical trials of pharmacological treatments for alcohol use disorder. Alcohol Clin Exp Res. 2020;44(10):1933–51. https://​doi.​org/​10.​1111/​acer.​14440.
39.
go back to reference Skinner HA HJ. Alcohol dependence scale (ADS): user’s guide. Addiction Research Foundation. 1984 Skinner HA HJ. Alcohol dependence scale (ADS): user’s guide. Addiction Research Foundation. 1984
40.
go back to reference Mason BJ. Looking Back, Looking forward: current medications and innovative potential medications to treat alcohol use disorder. Alcohol Res. 2022;42(1):11.PubMedPubMedCentralCrossRef Mason BJ. Looking Back, Looking forward: current medications and innovative potential medications to treat alcohol use disorder. Alcohol Res. 2022;42(1):11.PubMedPubMedCentralCrossRef
41.
go back to reference Fuller RK, Roth HP. Disulfiram for the treatment of alcoholism. An evaluation in 128 men. Ann Intern Med. 1979;90(6):901–4.PubMedCrossRef Fuller RK, Roth HP. Disulfiram for the treatment of alcoholism. An evaluation in 128 men. Ann Intern Med. 1979;90(6):901–4.PubMedCrossRef
42.
go back to reference Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A Veterans Adm Coop Study JAMA. 1986;256(11):1449–55. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A Veterans Adm Coop Study JAMA. 1986;256(11):1449–55.
43.
go back to reference Ling W, Weiss DG, Charuvastra VC, O’Brien CP. Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration Cooperative Study. Arch Gen Psychiatry. 1983;40(8):851–4.PubMedCrossRef Ling W, Weiss DG, Charuvastra VC, O’Brien CP. Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration Cooperative Study. Arch Gen Psychiatry. 1983;40(8):851–4.PubMedCrossRef
44.
go back to reference Aguiar P, Neto D, Lambaz R, Chick J, Ferrinho P. Prognostic factors during outpatient treatment for alcohol dependence: cohort study with 6 months of treatment follow-up. Alcohol Alcohol. 2012;47(6):702–10.PubMedCrossRef Aguiar P, Neto D, Lambaz R, Chick J, Ferrinho P. Prognostic factors during outpatient treatment for alcohol dependence: cohort study with 6 months of treatment follow-up. Alcohol Alcohol. 2012;47(6):702–10.PubMedCrossRef
45.
go back to reference Nich C, McCance-Katz EF, Petrakis IL, Cubells JF, Rounsaville BJ, Carroll KM. Sex differences in cocaine-dependent individuals’ response to disulfiram treatment. Addict Behav. 2004;29(6):1123–8.PubMedPubMedCentralCrossRef Nich C, McCance-Katz EF, Petrakis IL, Cubells JF, Rounsaville BJ, Carroll KM. Sex differences in cocaine-dependent individuals’ response to disulfiram treatment. Addict Behav. 2004;29(6):1123–8.PubMedPubMedCentralCrossRef
46.
go back to reference DeVito EE, Babuscio TA, Nich C, Ball SA, Carroll KM. Gender differences in clinical outcomes for cocaine dependence: randomized clinical trials of behavioral therapy and disulfiram. Drug Alcohol Depend. 2014;145:156–67.PubMedCrossRef DeVito EE, Babuscio TA, Nich C, Ball SA, Carroll KM. Gender differences in clinical outcomes for cocaine dependence: randomized clinical trials of behavioral therapy and disulfiram. Drug Alcohol Depend. 2014;145:156–67.PubMedCrossRef
47.
go back to reference Serova L, Rivkin M, Nakashima A, Sabban EL. Estradiol stimulates gene expression of norepinephrine biosynthetic enzymes in rat locus coeruleus. Neuroendocrinology. 2002;75(3):193–200.PubMedCrossRef Serova L, Rivkin M, Nakashima A, Sabban EL. Estradiol stimulates gene expression of norepinephrine biosynthetic enzymes in rat locus coeruleus. Neuroendocrinology. 2002;75(3):193–200.PubMedCrossRef
48.
go back to reference Agabio R, Pani PP, Preti A, Gessa GL, Franconi F. Efficacy of medications approved for the treatment of alcohol dependence and alcohol withdrawal syndrome in female patients: a descriptive review. Eur Addict Res. 2016;22(1):1–16.PubMedCrossRef Agabio R, Pani PP, Preti A, Gessa GL, Franconi F. Efficacy of medications approved for the treatment of alcohol dependence and alcohol withdrawal syndrome in female patients: a descriptive review. Eur Addict Res. 2016;22(1):1–16.PubMedCrossRef
49.
go back to reference Greenfield SF, Pettinati HM, O’Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34(10):1803–12.PubMedPubMedCentralCrossRef Greenfield SF, Pettinati HM, O’Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34(10):1803–12.PubMedPubMedCentralCrossRef
50.•
go back to reference Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012;36(3):497–508. Individual patient data meta-analysis examining gender specific differences in the efficacy, safety, and tolerability of acamprosate treatment for alcohol use disorder using data from 22 multi-national randomized clinical trials.PubMedCrossRef Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012;36(3):497–508. Individual patient data meta-analysis examining gender specific differences in the efficacy, safety, and tolerability of acamprosate treatment for alcohol use disorder using data from 22 multi-national randomized clinical trials.PubMedCrossRef
51.
go back to reference Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet. 1998;35(5):331–45.PubMedCrossRef Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet. 1998;35(5):331–45.PubMedCrossRef
53.
go back to reference Rosenthal RN, Gage A, Perhach JL, Goodman AM. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med. 2008;2(1):40–50.PubMedCrossRef Rosenthal RN, Gage A, Perhach JL, Goodman AM. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med. 2008;2(1):40–50.PubMedCrossRef
54.
go back to reference Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–25.PubMedCrossRef Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–25.PubMedCrossRef
55.
go back to reference Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR. Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res. 2006;30(5):860–5.PubMedCrossRef Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR. Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res. 2006;30(5):860–5.PubMedCrossRef
56.
go back to reference O’Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res. 2007;31(4):625–34.PubMedCrossRef O’Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res. 2007;31(4):625–34.PubMedCrossRef
57.
go back to reference Pettinati HM, Kampman KM, Lynch KG, Suh JJ, Dackis CA, Oslin DW, et al. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat. 2008;34(4):378–90.PubMedCrossRef Pettinati HM, Kampman KM, Lynch KG, Suh JJ, Dackis CA, Oslin DW, et al. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat. 2008;34(4):378–90.PubMedCrossRef
58.
go back to reference Suh JJ, Pettinati HM, Kampman KM, O’Brien CP. Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict. 2008;17(6):463–8.PubMedPubMedCentralCrossRef Suh JJ, Pettinati HM, Kampman KM, O’Brien CP. Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict. 2008;17(6):463–8.PubMedPubMedCentralCrossRef
59.
go back to reference Baros AM, Latham PK, Anton RF. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008;32(5):771–6.PubMedPubMedCentralCrossRef Baros AM, Latham PK, Anton RF. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008;32(5):771–6.PubMedPubMedCentralCrossRef
60.
go back to reference O’Malley SS, Krishnan-Sarin S, Farren C, O’Connor PG. Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol. 2000;20(1):69–76.PubMedCrossRef O’Malley SS, Krishnan-Sarin S, Farren C, O’Connor PG. Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol. 2000;20(1):69–76.PubMedCrossRef
61.
go back to reference Herbeck DM, Jeter KE, Cousins SJ, Abdelmaksoud R, Crevecoeur-MacPhail D. Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone. J Addict Dis. 2016;35(4):305–14.PubMedCrossRef Herbeck DM, Jeter KE, Cousins SJ, Abdelmaksoud R, Crevecoeur-MacPhail D. Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone. J Addict Dis. 2016;35(4):305–14.PubMedCrossRef
62.
go back to reference Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology. 2001;154(4):397–402.PubMedCrossRef Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology. 2001;154(4):397–402.PubMedCrossRef
63.
go back to reference Roche DJ, King AC. Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase. Psychoneuroendocrinology. 2015;52:59–71.PubMedCrossRef Roche DJ, King AC. Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase. Psychoneuroendocrinology. 2015;52:59–71.PubMedCrossRef
64.•
go back to reference Canidate SS, Carnaby GD, Cook CL, Cook RL. A systematic review of naltrexone for attenuating alcohol consumption in women with alcohol use disorders. Alcohol Clin Exp Res. 2017;41(3):466–72. A systematic review of naltrexone for the treatment of alcohol use disorder in women.PubMedPubMedCentralCrossRef Canidate SS, Carnaby GD, Cook CL, Cook RL. A systematic review of naltrexone for attenuating alcohol consumption in women with alcohol use disorders. Alcohol Clin Exp Res. 2017;41(3):466–72. A systematic review of naltrexone for the treatment of alcohol use disorder in women.PubMedPubMedCentralCrossRef
65.
go back to reference Nieto SJ, Quave CB, Kosten TA. Naltrexone alters alcohol self-administration behaviors and hypothalamic-pituitary-adrenal axis activity in a sex-dependent manner in rats. Pharmacol Biochem Behav. 2018;167:50–9.PubMedPubMedCentralCrossRef Nieto SJ, Quave CB, Kosten TA. Naltrexone alters alcohol self-administration behaviors and hypothalamic-pituitary-adrenal axis activity in a sex-dependent manner in rats. Pharmacol Biochem Behav. 2018;167:50–9.PubMedPubMedCentralCrossRef
66.
go back to reference Zhou Y, Leri F, Low MJ, Kreek MJ. Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice. Pharmacol Biochem Behav. 2019;181:28–36.PubMedPubMedCentralCrossRef Zhou Y, Leri F, Low MJ, Kreek MJ. Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice. Pharmacol Biochem Behav. 2019;181:28–36.PubMedPubMedCentralCrossRef
67.
go back to reference Matzeu A, Terenius L, Martin-Fardon R. Exploring sex differences in the attenuation of ethanol drinking by naltrexone in dependent rats during early and protracted abstinence. Alcohol Clin Exp Res. 2018;42(12):2466–78.PubMedPubMedCentralCrossRef Matzeu A, Terenius L, Martin-Fardon R. Exploring sex differences in the attenuation of ethanol drinking by naltrexone in dependent rats during early and protracted abstinence. Alcohol Clin Exp Res. 2018;42(12):2466–78.PubMedPubMedCentralCrossRef
68.
go back to reference Zhou Y, Kreek MJ. Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice. Brain Res. 2019;1724:146410.PubMedPubMedCentralCrossRef Zhou Y, Kreek MJ. Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice. Brain Res. 2019;1724:146410.PubMedPubMedCentralCrossRef
69.
go back to reference Chick J, Andersohn F, Guillo S, Borchert K, Toussi M, Braun S, et al. Safety and persistence of nalmefene treatment for alcohol dependence. Results from Two Post-authorisation Safety Studies. Alcohol. 2021;56(5):556–64.CrossRef Chick J, Andersohn F, Guillo S, Borchert K, Toussi M, Braun S, et al. Safety and persistence of nalmefene treatment for alcohol dependence. Results from Two Post-authorisation Safety Studies. Alcohol. 2021;56(5):556–64.CrossRef
70.
go back to reference Aubin HJ, Dureau-Pournin C, Falissard B, Paille F, Rigaud A, Micon S, et al. Use of nalmefene in routine practice: results from a French prospective cohort study and a national database analysis. Alcohol. 2021;56(5):545–55.CrossRef Aubin HJ, Dureau-Pournin C, Falissard B, Paille F, Rigaud A, Micon S, et al. Use of nalmefene in routine practice: results from a French prospective cohort study and a national database analysis. Alcohol. 2021;56(5):545–55.CrossRef
71.•
go back to reference Hashimoto N, Habu H, Takao S, Sakamoto S, Okahisa Y, Matsuo K, et al. Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: an exploratory analysis. Drug Alcohol Depend. 2022;233:109365. Study examining clinical moderators that affect treatment response to nalmefene in alcohol use disorder.PubMedCrossRef Hashimoto N, Habu H, Takao S, Sakamoto S, Okahisa Y, Matsuo K, et al. Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: an exploratory analysis. Drug Alcohol Depend. 2022;233:109365. Study examining clinical moderators that affect treatment response to nalmefene in alcohol use disorder.PubMedCrossRef
72.
go back to reference Castera P, Stewart E, Grosskopf J, Brotons C, Brix Schou M, Zhang D, et al. Nalmefene, Given as needed, in the routine treatment of patients with alcohol dependence: an interventional, open-label study in primary care. Eur Addict Res. 2018;24(6):293–303.PubMedCrossRef Castera P, Stewart E, Grosskopf J, Brotons C, Brix Schou M, Zhang D, et al. Nalmefene, Given as needed, in the routine treatment of patients with alcohol dependence: an interventional, open-label study in primary care. Eur Addict Res. 2018;24(6):293–303.PubMedCrossRef
73.
go back to reference Gual A, He Y, Torup L, Van den Brink W, Mann K. Group ES A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11):1432–42.PubMedCrossRef Gual A, He Y, Torup L, Van den Brink W, Mann K. Group ES A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11):1432–42.PubMedCrossRef
75.
go back to reference Calleja-Conde J, Echeverry-Alzate V, Giné E, Bühler KM, Nadal R, Maldonado R, et al. Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood. Br J Pharmacol. 2016;173(16):2490–505.PubMedPubMedCentralCrossRef Calleja-Conde J, Echeverry-Alzate V, Giné E, Bühler KM, Nadal R, Maldonado R, et al. Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood. Br J Pharmacol. 2016;173(16):2490–505.PubMedPubMedCentralCrossRef
76.
go back to reference Chartoff EH, Mavrikaki M (2015) Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction. Frontiers in Neuroscience 9 Chartoff EH, Mavrikaki M (2015) Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction. Frontiers in Neuroscience 9
77.
go back to reference Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, et al. A randomized, placebo-controlled study of high-dose Baclofen in alcohol-dependent patients—the ALPADIR study. Alcohol. 2017;52(4):439–46.CrossRef Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, et al. A randomized, placebo-controlled study of high-dose Baclofen in alcohol-dependent patients—the ALPADIR study. Alcohol. 2017;52(4):439–46.CrossRef
78.
go back to reference Morley KC, Louie E, Hurzeler T, Baillie A, Dore G, Phung N, et al. Sex as a potential moderator for Baclofen response in the treatment of alcohol dependence. Front Glob Womens Health. 2022;3:807269.PubMedPubMedCentralCrossRef Morley KC, Louie E, Hurzeler T, Baillie A, Dore G, Phung N, et al. Sex as a potential moderator for Baclofen response in the treatment of alcohol dependence. Front Glob Womens Health. 2022;3:807269.PubMedPubMedCentralCrossRef
79.
go back to reference Logge W, Baillie A, Haber P, Towers E, Riordan BC, Morley K. Sex differences in the interrelations between stress, craving and alcohol consumption across individuals and time during baclofen treatment for alcohol dependence. Addict Behav. 2023;136:107462.PubMedCrossRef Logge W, Baillie A, Haber P, Towers E, Riordan BC, Morley K. Sex differences in the interrelations between stress, craving and alcohol consumption across individuals and time during baclofen treatment for alcohol dependence. Addict Behav. 2023;136:107462.PubMedCrossRef
80.
go back to reference Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the Treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol. 2014;49(6):654–60.CrossRef Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the Treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol. 2014;49(6):654–60.CrossRef
81.•
go back to reference Garbutt JC, Kampov-Polevoy AB, Pedersen C, Stansbury M, Jordan R, Willing L, et al (2021) Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacology 46(13):2250-6. Double-blind, randomized, placebo-controlled trial of baclofen for the treatment of alcohol use disorder, with a focus on potential moderators of baclofen response (i.e., sex, dose). Garbutt JC, Kampov-Polevoy AB, Pedersen C, Stansbury M, Jordan R, Willing L, et al (2021) Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacology 46(13):2250-6. Double-blind, randomized, placebo-controlled trial of baclofen for the treatment of alcohol use disorder, with a focus on potential moderators of baclofen response (i.e., sex, dose).
82.
go back to reference Rigal L, Legay Hoang L, Alexandre-Dubroeucq C, Pinot J, Le Jeunne C, Jaury P. Tolerability of high-dose Baclofen in the treatment of patients with alcohol disorders: a retrospective study. Alcohol Alcohol. 2015;50(5):551–7.PubMedCrossRef Rigal L, Legay Hoang L, Alexandre-Dubroeucq C, Pinot J, Le Jeunne C, Jaury P. Tolerability of high-dose Baclofen in the treatment of patients with alcohol disorders: a retrospective study. Alcohol Alcohol. 2015;50(5):551–7.PubMedCrossRef
83.
go back to reference Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34(11):1849–57.PubMedPubMedCentralCrossRef Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34(11):1849–57.PubMedPubMedCentralCrossRef
84.
go back to reference Haile CN, Carper BA, Nolen TL, Kosten TA. The GABAB receptor positive allosteric modulator ASP8062 reduces operant alcohol self-administration in male and female Sprague Dawley rats. Psychopharmacology. 2021;238(9):2587–600.PubMedCrossRef Haile CN, Carper BA, Nolen TL, Kosten TA. The GABAB receptor positive allosteric modulator ASP8062 reduces operant alcohol self-administration in male and female Sprague Dawley rats. Psychopharmacology. 2021;238(9):2587–600.PubMedCrossRef
85.
go back to reference Bauer MR, Hernandez M, Kasten CR, Boehm SL 2nd. Systemic administration of racemic baclofen reduces both acquisition and maintenance of alcohol consumption in male and female mice. Alcohol. 2022;103:25–35.PubMedPubMedCentralCrossRef Bauer MR, Hernandez M, Kasten CR, Boehm SL 2nd. Systemic administration of racemic baclofen reduces both acquisition and maintenance of alcohol consumption in male and female mice. Alcohol. 2022;103:25–35.PubMedPubMedCentralCrossRef
86.
go back to reference Guiraud J, Addolorato G, Antonelli M, Aubin HJ, de Bejczy A, Benyamina A, et al. Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2022;36(10):1136–45.PubMedPubMedCentralCrossRef Guiraud J, Addolorato G, Antonelli M, Aubin HJ, de Bejczy A, Benyamina A, et al. Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2022;36(10):1136–45.PubMedPubMedCentralCrossRef
87.
go back to reference Maccioni P, Pes D, Fantini N, Carai MA, Gessa GL, Colombo G. Gamma-hydroxybutyric acid (GHB) suppresses alcohol’s motivational properties in alcohol-preferring rats. Alcohol. 2008;42(2):107–13.PubMedCrossRef Maccioni P, Pes D, Fantini N, Carai MA, Gessa GL, Colombo G. Gamma-hydroxybutyric acid (GHB) suppresses alcohol’s motivational properties in alcohol-preferring rats. Alcohol. 2008;42(2):107–13.PubMedCrossRef
88.
go back to reference Colombo G, Carai MA, Gessa GL. Suppression by γ-hydroxybutyric acid of “alcohol deprivation effect” in rats: preclinical evidence of its anti-relapse properties. Front Psychiatry. 2012;3:95.PubMedPubMedCentralCrossRef Colombo G, Carai MA, Gessa GL. Suppression by γ-hydroxybutyric acid of “alcohol deprivation effect” in rats: preclinical evidence of its anti-relapse properties. Front Psychiatry. 2012;3:95.PubMedPubMedCentralCrossRef
89.
go back to reference Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction. 2008;103(4):687–94.PubMedCrossRef Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction. 2008;103(4):687–94.PubMedCrossRef
90.
go back to reference Fluyau D, Kailasam VK, Pierre CG. A Bayesian meta-analysis of topiramate’s effectiveness for individuals with alcohol use disorder. J Psychopharmacol. 2023;37(2):155–63.PubMedCrossRef Fluyau D, Kailasam VK, Pierre CG. A Bayesian meta-analysis of topiramate’s effectiveness for individuals with alcohol use disorder. J Psychopharmacol. 2023;37(2):155–63.PubMedCrossRef
91.
go back to reference Hargreaves GA, McGregor IS. Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcohol Clin Exp Res. 2007;31(11):1900–7.PubMedCrossRef Hargreaves GA, McGregor IS. Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcohol Clin Exp Res. 2007;31(11):1900–7.PubMedCrossRef
92.
go back to reference Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C. Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Behav. 2007;87(1):65–72.PubMedPubMedCentralCrossRef Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C. Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Behav. 2007;87(1):65–72.PubMedPubMedCentralCrossRef
93.
go back to reference Moore CF, Lynch WJ. Alcohol preferring (P) rats as a model for examining sex differences in alcohol use disorder and its treatment. Pharmacol Biochem Behav. 2015;132:1–9.PubMedPubMedCentralCrossRef Moore CF, Lynch WJ. Alcohol preferring (P) rats as a model for examining sex differences in alcohol use disorder and its treatment. Pharmacol Biochem Behav. 2015;132:1–9.PubMedPubMedCentralCrossRef
94.•
go back to reference O’Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM, et al (2018) Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial. JAMA Psychiatry 75(2):129-38. A randomized, double-blind, placebo-controlled trial testing the efficacy of varenicline for patients with alcohol use disorder and comorbid smoking. O’Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM, et al (2018) Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial. JAMA Psychiatry 75(2):129-38. A randomized, double-blind, placebo-controlled trial testing the efficacy of varenicline for patients with alcohol use disorder and comorbid smoking.
95.
96.
go back to reference Halperin AC, McAfee TA, Jack LM, Catz SL, McClure JB, Deprey TM, et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat. 2009;36(4):428–34.PubMedCrossRef Halperin AC, McAfee TA, Jack LM, Catz SL, McClure JB, Deprey TM, et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat. 2009;36(4):428–34.PubMedCrossRef
97.
go back to reference Ravva P, Gastonguay MR, French JL, Tensfeldt TG, Faessel HM. Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation. Clin Pharmacol Ther. 2010;87(3):336–44.PubMedCrossRef Ravva P, Gastonguay MR, French JL, Tensfeldt TG, Faessel HM. Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation. Clin Pharmacol Ther. 2010;87(3):336–44.PubMedCrossRef
98.
go back to reference Falk DE, Castle I-JP, Ryan M, Fertig J, Litten RZ. Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis. J Addict Med. 2015;9(4):296–303.PubMedPubMedCentralCrossRef Falk DE, Castle I-JP, Ryan M, Fertig J, Litten RZ. Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis. J Addict Med. 2015;9(4):296–303.PubMedPubMedCentralCrossRef
99.
go back to reference Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7(4):277–86.PubMedPubMedCentralCrossRef Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7(4):277–86.PubMedPubMedCentralCrossRef
100.
go back to reference Kamens HM, Silva C, Peck C, Miller CN. Varenicline modulates ethanol and saccharin consumption in adolescent male and female C57BL/6J mice. Brain Res Bull. 2018;138:20–5.PubMedCrossRef Kamens HM, Silva C, Peck C, Miller CN. Varenicline modulates ethanol and saccharin consumption in adolescent male and female C57BL/6J mice. Brain Res Bull. 2018;138:20–5.PubMedCrossRef
101.
go back to reference Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284(8):963–71.PubMedCrossRef Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284(8):963–71.PubMedCrossRef
102.
go back to reference Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, et al. Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings. Alcohol. 2014;48(6):515–22.PubMedPubMedCentralCrossRef Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, et al. Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings. Alcohol. 2014;48(6):515–22.PubMedPubMedCentralCrossRef
103.
go back to reference Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, et al. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest. 2015;125(8):3193–7.PubMedPubMedCentralCrossRef Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, et al. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest. 2015;125(8):3193–7.PubMedPubMedCentralCrossRef
104.
go back to reference Donoghue K, Rose A, Coulton S, Coleman R, Milward J, Philips T, et al. Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence. Trials. 2020;21(1):796.PubMedPubMedCentralCrossRef Donoghue K, Rose A, Coulton S, Coleman R, Milward J, Philips T, et al. Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence. Trials. 2020;21(1):796.PubMedPubMedCentralCrossRef
105.
go back to reference Donoghue K, Rose A, Coulton S, Milward J, Reed K, Drummond C, et al. Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. BMC Psychiatry. 2016;16:40.PubMedPubMedCentralCrossRef Donoghue K, Rose A, Coulton S, Milward J, Reed K, Drummond C, et al. Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. BMC Psychiatry. 2016;16:40.PubMedPubMedCentralCrossRef
106.
go back to reference Simms JA, Haass-Koffler CL, Bito-Onon J, Li R, Bartlett SE. Mifepristone in the central nucleus of the amygdala reduces Yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacology. 2012;37(4):906–18.PubMedCrossRef Simms JA, Haass-Koffler CL, Bito-Onon J, Li R, Bartlett SE. Mifepristone in the central nucleus of the amygdala reduces Yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacology. 2012;37(4):906–18.PubMedCrossRef
107.
go back to reference Benvenuti F, Cannella N, Stopponi S, Soverchia L, Ubaldi M, Lunerti V, et al. Effect of glucocorticoid receptor antagonism on alcohol self-administration in genetically-selected Marchigian Sardinian alcohol-preferring and non-preferring Wistar rats. Int J Mol Sci. 2021;22:8.CrossRef Benvenuti F, Cannella N, Stopponi S, Soverchia L, Ubaldi M, Lunerti V, et al. Effect of glucocorticoid receptor antagonism on alcohol self-administration in genetically-selected Marchigian Sardinian alcohol-preferring and non-preferring Wistar rats. Int J Mol Sci. 2021;22:8.CrossRef
108.
go back to reference Jimenez VA, Walter NAR, Shnitko TA, Newman N, Diem K, Vanderhooft L, et al. Mifepristone decreases chronic voluntary ethanol consumption in Rhesus Macaques. J Pharmacol Exp Ther. 2020;375(2):258–67.PubMedPubMedCentralCrossRef Jimenez VA, Walter NAR, Shnitko TA, Newman N, Diem K, Vanderhooft L, et al. Mifepristone decreases chronic voluntary ethanol consumption in Rhesus Macaques. J Pharmacol Exp Ther. 2020;375(2):258–67.PubMedPubMedCentralCrossRef
109.
go back to reference Logrip ML, Gainey SC. Sex differences in the long-term effects of past stress on alcohol self-administration, glucocorticoid sensitivity and phosphodiesterase 10A expression. Neuropharmacology. 2020;164:107857.PubMedCrossRef Logrip ML, Gainey SC. Sex differences in the long-term effects of past stress on alcohol self-administration, glucocorticoid sensitivity and phosphodiesterase 10A expression. Neuropharmacology. 2020;164:107857.PubMedCrossRef
110.
go back to reference Chen W, Xiao Y, Cheng Y, Chen J, Chen J, Jiang K, et al. Pharmacokinetic differences of mifepristone between sexes in animals. J Pharm Biomed Anal. 2018;154:108–15.PubMedCrossRef Chen W, Xiao Y, Cheng Y, Chen J, Chen J, Jiang K, et al. Pharmacokinetic differences of mifepristone between sexes in animals. J Pharm Biomed Anal. 2018;154:108–15.PubMedCrossRef
111.
go back to reference Leggio L, Kenna GA. Commentary: Doxazosin for alcoholism. Alcohol Clin Exp Res. 2013;37(2):191–3.PubMedCrossRef Leggio L, Kenna GA. Commentary: Doxazosin for alcoholism. Alcohol Clin Exp Res. 2013;37(2):191–3.PubMedCrossRef
112.
go back to reference Petrakis IL, Desai N, Gueorguieva R, Arias A, O’Brien E, Jane JS, et al. Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: a clinical trial. Alcohol Clin Exp Res. 2016;40(1):178–86.PubMedCrossRef Petrakis IL, Desai N, Gueorguieva R, Arias A, O’Brien E, Jane JS, et al. Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: a clinical trial. Alcohol Clin Exp Res. 2016;40(1):178–86.PubMedCrossRef
113.
go back to reference Simpson TL, Malte CA, Dietel B, Tell D, Pocock I, Lyons R, et al. A pilot trial of Prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2015;39(5):808–17.PubMedPubMedCentralCrossRef Simpson TL, Malte CA, Dietel B, Tell D, Pocock I, Lyons R, et al. A pilot trial of Prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2015;39(5):808–17.PubMedPubMedCentralCrossRef
114.
go back to reference Simpson TL, Saxon AJ, Stappenbeck C, Malte CA, Lyons R, Tell D, et al. Double-blind randomized clinical trial of Prazosin for alcohol use disorder. Am J Psychiatry. 2018;175(12):1216–24.PubMedPubMedCentralCrossRef Simpson TL, Saxon AJ, Stappenbeck C, Malte CA, Lyons R, Tell D, et al. Double-blind randomized clinical trial of Prazosin for alcohol use disorder. Am J Psychiatry. 2018;175(12):1216–24.PubMedPubMedCentralCrossRef
115.
go back to reference Sinha R, Wemm S, Fogelman N, Milivojevic V, Morgan PM, Angarita GA, et al. Moderation of Prazosin’s efficacy by alcohol withdrawal symptoms. Am J Psychiatry. 2021;178(5):447–58.PubMedCrossRef Sinha R, Wemm S, Fogelman N, Milivojevic V, Morgan PM, Angarita GA, et al. Moderation of Prazosin’s efficacy by alcohol withdrawal symptoms. Am J Psychiatry. 2021;178(5):447–58.PubMedCrossRef
116.
go back to reference Milivojevic V, Angarita GA, Hermes G, Sinha R, Fox HC. Effects of Prazosin on provoked alcohol craving and autonomic and neuroendocrine response to stress in alcohol use disorder. Alcohol Clin Exp Res. 2020;44(7):1488–96.PubMedPubMedCentralCrossRef Milivojevic V, Angarita GA, Hermes G, Sinha R, Fox HC. Effects of Prazosin on provoked alcohol craving and autonomic and neuroendocrine response to stress in alcohol use disorder. Alcohol Clin Exp Res. 2020;44(7):1488–96.PubMedPubMedCentralCrossRef
117.
go back to reference Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, et al. Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addict Biol. 2016;21(4):904–14.PubMedCrossRef Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, et al. Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addict Biol. 2016;21(4):904–14.PubMedCrossRef
118.
go back to reference Lopez MF, Reasons SE, Carper BA, Nolen TL, Williams RL, Becker HC. Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress. Alcohol. 2020;89:37–42.PubMedPubMedCentralCrossRef Lopez MF, Reasons SE, Carper BA, Nolen TL, Williams RL, Becker HC. Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress. Alcohol. 2020;89:37–42.PubMedPubMedCentralCrossRef
119.
go back to reference Loche A, Simonetti F, Lobina C, Carai MA, Colombo G, Castelli MP, et al. Anti-alcohol and anxiolytic properties of a new chemical entity, GET73. Front Psychiatry. 2012;3:8.PubMedPubMedCentralCrossRef Loche A, Simonetti F, Lobina C, Carai MA, Colombo G, Castelli MP, et al. Anti-alcohol and anxiolytic properties of a new chemical entity, GET73. Front Psychiatry. 2012;3:8.PubMedPubMedCentralCrossRef
120.
go back to reference Zhou Y, Colombo G, Carai MA, Ho A, Gessa GL, Kreek MJ. Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats. Alcohol Clin Exp Res. 2011;35(10):1876–83.PubMedPubMedCentralCrossRef Zhou Y, Colombo G, Carai MA, Ho A, Gessa GL, Kreek MJ. Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats. Alcohol Clin Exp Res. 2011;35(10):1876–83.PubMedPubMedCentralCrossRef
121.
go back to reference Edwards S, Guerrero M, Ghoneim OM, Roberts E, Koob GF. Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats. Addict Biol. 2012;17(1):76–85.PubMedCrossRef Edwards S, Guerrero M, Ghoneim OM, Roberts E, Koob GF. Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats. Addict Biol. 2012;17(1):76–85.PubMedCrossRef
122.
go back to reference Gomez JL, Cunningham CL, Finn DA, Young EA, Helpenstell LK, Schuette LM, et al. Differential effects of ghrelin antagonists on alcohol drinking and reinforcement in mouse and rat models of alcohol dependence. Neuropharmacology. 2015;97:182–93.PubMedPubMedCentralCrossRef Gomez JL, Cunningham CL, Finn DA, Young EA, Helpenstell LK, Schuette LM, et al. Differential effects of ghrelin antagonists on alcohol drinking and reinforcement in mouse and rat models of alcohol dependence. Neuropharmacology. 2015;97:182–93.PubMedPubMedCentralCrossRef
123.
go back to reference Kaur S, Ryabinin AE. Ghrelin receptor antagonism decreases alcohol consumption and activation of perioculomotor urocortin-containing neurons. Alcohol Clin Exp Res. 2010;34(9):1525–34.PubMedPubMedCentralCrossRef Kaur S, Ryabinin AE. Ghrelin receptor antagonism decreases alcohol consumption and activation of perioculomotor urocortin-containing neurons. Alcohol Clin Exp Res. 2010;34(9):1525–34.PubMedPubMedCentralCrossRef
124.
go back to reference De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, et al. Therapeutic prospects of Cannabidiol for alcohol use disorder and alcohol-related damages on the liver and the brain. Front Pharmacol. 2019;10:627.PubMedPubMedCentralCrossRef De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, et al. Therapeutic prospects of Cannabidiol for alcohol use disorder and alcohol-related damages on the liver and the brain. Front Pharmacol. 2019;10:627.PubMedPubMedCentralCrossRef
125.
go back to reference Lee MR, Tapocik JD, Ghareeb M, Schwandt ML, Dias AA, Le AN, et al. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. Mol Psychiatry. 2020;25(2):461–75.PubMedCrossRef Lee MR, Tapocik JD, Ghareeb M, Schwandt ML, Dias AA, Le AN, et al. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. Mol Psychiatry. 2020;25(2):461–75.PubMedCrossRef
126.
go back to reference Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, et al. A phase 2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence. Neuropsychopharmacology. 2017;42(5):1012–23.PubMedCrossRef Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, et al. A phase 2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence. Neuropsychopharmacology. 2017;42(5):1012–23.PubMedCrossRef
127.
go back to reference Stevenson JR, Francomacaro LM, Bohidar AE, Young KA, Pesarchick BF, Buirkle JM, et al. Ghrelin receptor (GHS-R1A) antagonism alters preference for ethanol and sucrose in a concentration-dependent manner in prairie voles. Physiol Behav. 2016;155:231–6.PubMedCrossRef Stevenson JR, Francomacaro LM, Bohidar AE, Young KA, Pesarchick BF, Buirkle JM, et al. Ghrelin receptor (GHS-R1A) antagonism alters preference for ethanol and sucrose in a concentration-dependent manner in prairie voles. Physiol Behav. 2016;155:231–6.PubMedCrossRef
128.
go back to reference Bold KW, Zweben A, Fucito LM, Piepmeier ME, Muvvala S, Wu R, et al. Longitudinal findings from a randomized clinical trial of Varenicline for alcohol use disorder with comorbid cigarette smoking. Alcohol Clin Exp Res. 2019;43(5):937–44.PubMedPubMedCentralCrossRef Bold KW, Zweben A, Fucito LM, Piepmeier ME, Muvvala S, Wu R, et al. Longitudinal findings from a randomized clinical trial of Varenicline for alcohol use disorder with comorbid cigarette smoking. Alcohol Clin Exp Res. 2019;43(5):937–44.PubMedPubMedCentralCrossRef
129.
go back to reference Agabio R, Pisanu C, Gessa GL, Franconi F. Sex differences in alcohol use disorder. Curr Med Chem. 2017;24(24):2661–70.PubMedCrossRef Agabio R, Pisanu C, Gessa GL, Franconi F. Sex differences in alcohol use disorder. Curr Med Chem. 2017;24(24):2661–70.PubMedCrossRef
Metadata
Title
Pharmacological Treatments for Alcohol Use Disorder: Considering the Role of Sex and Gender
Authors
Dylan E. Kirsch
Malia A. Belnap
Elizabeth M. Burnette
Erica N. Grodin
Lara A. Ray
Publication date
03-01-2024
Publisher
Springer International Publishing
Published in
Current Addiction Reports / Issue 1/2024
Electronic ISSN: 2196-2952
DOI
https://doi.org/10.1007/s40429-023-00535-x